Kiniksa Pharmaceuticals (NASDAQ:KNSA) Posts Earnings Results, Misses Estimates By $0.11 EPS

Kiniksa Pharmaceuticals (NASDAQ:KNSA) posted its quarterly earnings data on Tuesday. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.11), Briefing.com reports. The firm had revenue of $79.90 million during the quarter, compared to analysts’ expectations of $76.97 million. Kiniksa Pharmaceuticals had a net margin of 5.11% and a negative return on equity of 6.12%. The company’s quarterly revenue was up 65.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.18) EPS.

Kiniksa Pharmaceuticals Trading Up 4.2 %

Shares of KNSA stock traded up $0.75 during trading hours on Wednesday, hitting $18.43. 56,562 shares of the company were exchanged, compared to its average volume of 398,310. The firm has a fifty day simple moving average of $19.36 and a 200 day simple moving average of $18.00. Kiniksa Pharmaceuticals has a 52-week low of $10.65 and a 52-week high of $22.09. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of 100.84 and a beta of 0.27.

Insider Transactions at Kiniksa Pharmaceuticals

In related news, CAO Michael R. Megna sold 5,126 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total value of $111,695.54. Following the completion of the transaction, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at approximately $383,242.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CAO Michael R. Megna sold 5,126 shares of the firm’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $21.79, for a total value of $111,695.54. Following the completion of the transaction, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at approximately $383,242.52. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Michael R. Megna sold 9,659 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $21.45, for a total transaction of $207,185.55. Following the completion of the transaction, the chief accounting officer now directly owns 17,588 shares of the company’s stock, valued at $377,262.60. The disclosure for this sale can be found here. Insiders sold a total of 33,109 shares of company stock worth $709,929 in the last quarter. Insiders own 54.23% of the company’s stock.

Analysts Set New Price Targets

KNSA has been the subject of several analyst reports. TheStreet upgraded shares of Kiniksa Pharmaceuticals from a “d+” rating to a “c” rating in a research note on Thursday, February 29th. Wedbush reiterated an “outperform” rating and issued a $30.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Tuesday.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.